Breast cancer detection with a blood test: Syantra presents early data from …

Syantra Inc.

Calgary, AB (ots/PRNewswire)

Syantra, a precision medicine company that is changing the way cancer is diagnosed and treated, will present the results of the IDBC study at the 13th European Breast Cancer Conference, which will be held in Barcelona, ​​Spain, from November 16 to 18, 2022. place.

“We are delighted to have been selected for the Poster Spotlight Session by the Scientific Committee of the 13th EBCC. Our results will help the community better understand how whole blood analysis can be used in cancer detection and treatment,” said Kristina Rinker, PhD. “We look forward to discussing the latest results and collaborating with stakeholders who have advanced cancer detection and treatment. “

Professor Nigel Bundred, a surgical oncologist at Manchester University NHS Foundation Trust’s Wythenshawe Hospital, will present the study data during the Poster Spotlight Session.

“The results of the study are extremely promising. Although mammograms can save lives, many women with breast cancer go undetected. This is particularly true for young women with dense breasts, where breast cancer is difficult to detect on a mammogram,” said Professor Bundred. “More sensitive tests are needed to detect cancer earlier, when it may be easier to treat. We are pleased to present data that support the role of the blood test as an adjunct to standard imaging methods for breast cancer detection.”

Visit Syantra from 16 to 18 November 2022 at Stand #A1 at the Barcelona International Convention Center ( CCIB), Plaça de Willy Brandt, 11-14, 08019, Barcelona, ​​​​​​​​​Spain.

In addition to visiting our exhibition stand, also listen to our lecture and view our scientific poster.

Presentation information

Session Type: Spotlight Session poster

Meeting time: November 16, 2022, 13:30 to 14:20 CET (GMT+1)

Ort: Special poster exhibition area

Spokesman: Professor Nigel Bundred, MD, FRCS

Abstract: Whole blood screening for breast cancer: Analytical and clinical performance from an early analysis of the IDBC study

Information about Syantra

Syantra is a precision medicine company that is changing the way cancer is diagnosed and treated. Its flagship product is Syantra DXTM Breast Cancer, a minimally invasive and powerful blood test to detect breast cancer.

For more information visit:

Media Inquiries:

info@syantra.comPhoto –
View original content: idbc-cancer-at-the-13th-european-breast-cancer-conference-301673390.html

Original content from: Syantra Inc., transmitted by aktuell aktuell

Leave a Comment